Navigation Links
BioMS Medical to present at 2008 BIO International Convention
Date:6/12/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, June 12 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Business Forum at the 2008 BIO International Convention in San Diego, California.

WHEN: Friday June 20th at 10:15 am (PDT)

WHERE: San Diego Convention Center, San Diego

About the 2008 BIO International Convention

The 2008 BIO International Convention, hosted by the Biotechnology Industry Organization, will feature keynotes from industry and global leaders, more than 175 breakout sessions, business partnering meetings, and numerous networking events. The convention also includes more than 200,000 square feet of exhibitions showcasing the latest advancements in biotechnology alongside an array of potential partners, service providers, and state and international delegations. For more information visit http://www.bio2008.org/.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298 (dirucotide), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 (dirucotide) in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. BioMS Medical announces first quarter 2008 results
3. BioMs Medical to present at TIDES(R) Conference
4. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
5. BioMS Medical Provides Update On Pipeline Products
6. BioMS Medical announces conference call and web cast for Annual General Meeting
7. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
8. BioMS Medical to present at EQUITIES Conference
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. BioMS Medical to present at BioCentury Conference
11. BioMS Medical Announces 2007 Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... April 21, 2015  Novogen Limited (ASX:NRT; NASDAQ: ... advises that it has entered into definitive agreements ... shares plus one attaching 6-month option and half ... share issued, to institutional investors in ... placement for aggregate gross proceeds of approximately AU$15,500,000 ...
(Date:4/21/2015)... 2015 A leading manufacturer of stainless ... to discuss its custom fabrication services today at INTERPHEX ... which launched just prior to the INTERPHEX event. The ... 22 and 23) at the Javits Center in New ... world’s largest and most innovative pharmaceutical and biotech firms ...
(Date:4/20/2015)... Winston-Salem, NC and Champaign, IL (PRWEB) April 20, 2015 ... announced today the establishment of its 12th clinical research ... 2015, PMG Research has assumed operation of the clinical ... IL, expanding PMG’s footprint outside the Southeast to a ... site within a 150 multi-specialty physician practice enhances PMG’s ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3
... Phase 1 clinical studies support advancement to Phase 2 ... Roche polymerase inhibitors -, BRISBANE, Calif., Sept. 24 ... four abstracts from clinical and,in-vitro studies of ITMN-191 (R7227) ... American Association for the Study of Liver Diseases,(AASLD, Oct. ...
... new screening platform for antibody therapeutics, BASEL, ... today that it has completed the acquisition of ... of ARIUS Research (TSX: ARI). On,September 19th, the ... previously approved by the security holders and announced ...
... signing to follow his presentation, WASHINGTON, Sept. ... global marketplace, and the role of,financing are focus ... presentations will focus on the convergence of the,MedTech ... patient monitoring,technologies, critical issues to consider when entering ...
Cached Biology Technology:InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 2InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 3InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 4InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 5InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting 6Roche completes acquisition of ARIUS 2Former Speaker of the House Newt Gingrich Featured Wednesday 2
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... upcoming paper from Dr. David Wassarman (University of Wisconsin ... 1 issue of G&D lends new insight into the ... (A-T) is a rare, genetic immunodeficiency disease that affects ... cancer predisposition. A-T is caused by recessive mutations in ...
... to designing something, its hard to find a better ... principle, a diverse, interdisciplinary group of researchers at the ... to synthesize magnetic nanoparticles that could be used for ... high-density memory devices, or as magnetic seals in motors. ...
... nature vs. nurture debate is familiar to most people, ... two. A new paper published this week in the ... similar balance between the genes we inherit—nature—and the environment—nurture—in ... the age of personal genomics, in which each of ...
Cached Biology News:Researchers mimic bacteria to produce magnetic nanoparticles 2Researchers mimic bacteria to produce magnetic nanoparticles 3
X-Gal (5-Bromo-4-Chloro-3-Indoyl-beta -D-Galactopyranoside)...
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Biology Products: